LENZ Therapeutics, Inc. (LENZ)
After hours:
| Previous close | 17.69 |
| Open | 17.79 |
| Bid | 17.40 x 100 |
| Ask | 17.63 x 100 |
| Day's range | 17.31 - 17.98 |
| 52-week range | 2.01 - 24.59 |
| Volume | |
| Avg. volume | 195,445 |
| Market cap | 447.875M |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- GlobeNewswire
LENZ Therapeutics to Host Key Opinion Leader Event on June 18, 2024
Capstone data from Phase 3 CLARITY study to be presented Event to feature Key Opinion Leader and Principal Investigator perspectives on LNZ100 potential in presbyopia SAN DIEGO, June 10, 2024 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (Nasdaq: LENZ or “LENZ” or the “Company”), a late clinical-stage biopharmaceutical company focused on developing the first aceclidine-based eye drop to improve near vision in people with presbyopia, today announced that the Company will host a Key Opinion Leader (
- GlobeNewswire
LENZ Therapeutics to Present at the Jefferies Global Healthcare Conference
SAN DIEGO, May 30, 2024 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (Nasdaq: LENZ or “LENZ” or the “Company”), a late clinical-stage biopharmaceutical company focused on developing the first aceclidine-based eye drop that has been shown to improve near vision in people with presbyopia, today announced that Eef Schimmelpennink, President and Chief Executive Officer, will present and company management will participate in one-on-one meetings at the Jefferies Global Healthcare Conference being held
- GlobeNewswire
LENZ Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates
Reported positive topline data from Phase 3 CLARITY study for presbyopia; selected LNZ100 as lead candidate; New Drug Application submission anticipated in mid-2024 Capstone data from Phase 3 CLARITY study to be presented at Key Opinion Leader event planned for June 18, 2024 Completed merger with Graphite Bio and concurrent $53.5 million private placement Cash, cash equivalents and marketable securities of approximately $213.3 million as of March 31, 2024; cash runway anticipated to extend to po
